Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-21 09:00 am Purchase | 2025-02-20 | 13D | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 13,307,967 7.000% | 440,000 (+3.42%) | Filing History |
| 2025-02-18 5:21 pm Unchanged | 2025-02-18 | 13D | Arbutus Biopharma Corporation ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 20.500% | 0 (Unchanged) | Filing History |
| 2025-02-03 3:26 pm Purchase | 2024-12-31 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 21,524,661 11.400% | 2,132,173 (+10.99%) | Filing History |
| 2024-11-14 08:41 am Sale | 2024-09-30 | 13G | Arbutus Biopharma Corporation ABUS | Two Seas Capital LP | 8,387,388 4.400% | -654,539 (-7.24%) | Filing History |
| 2024-06-10 4:50 pm Purchase | 2024-05-31 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 19,392,488 10.300% | 17,954,224 (+1248.33%) | Filing History |
| 2024-05-17 09:03 am Unchanged | 2024-05-17 | 13D | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 12,867,967 6.800% | 0 (Unchanged) | Filing History |
| 2024-05-09 08:00 am Sale | 2024-05-02 | 13D | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 12,867,967 6.800% | -329,095 (-2.49%) | Filing History |
| 2024-02-14 4:38 pm Purchase | 2023-12-31 | 13G | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 13,197,062 7.900% | 3,183,163 (+31.79%) | Filing History |
| 2024-02-14 10:48 am Sale | 2023-12-31 | 13G | Arbutus Biopharma Corporation ABUS | Two Seas Capital LP | 9,041,927 5.400% | -461,176 (-4.85%) | Filing History |
| 2024-02-12 09:41 am Purchase | 2023-12-31 | 13G | Arbutus Biopharma Corporation ABUS | BlackRock Inc. BLK | 10,390,300 6.200% | 1,689,908 (+19.42%) | Filing |
| 2023-11-21 08:00 am Purchase | 2023-11-21 | 13G | Arbutus Biopharma Corporation ABUS | Two Seas Capital LP | 9,503,103 5.700% | 9,503,103 (New Position) | Filing History |
| 2023-09-11 5:07 pm Purchase | 2023-09-01 | 13G | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 10,013,899 6.000% | 10,013,899 (New Position) | Filing History |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | Arbutus Biopharma Corporation ABUS | BlackRock Inc. BLK | 8,700,392 5.600% | 8,700,392 (New Position) | Filing |
| 2022-02-14 09:36 am Sale | 2021-12-31 | 13G | Arbutus Biopharma Corporation ABUS | RTW Investments, LP | 2,504,493 1.700% | -3,473,862 (-58.11%) | Filing History |
| 2021-10-20 5:13 pm Purchase | 2021-10-18 | 13D | Arbutus Biopharma Corporation ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 29.100% | 22,833,922 (+142.59%) | Filing History |
| 2021-02-16 10:46 am Sale | 2020-12-31 | 13G | Arbutus Biopharma Corporation ABUS | Foresite Capital Fund IV, L.P. | 0 0.000% | -3,705,128 (Position Closed) | Filing History |
| 2021-02-12 09:23 am Purchase | 2020-12-31 | 13G | Arbutus Biopharma Corporation ABUS | RTW Investments, LP | 5,978,355 7.050% | 311,601 (+5.50%) | Filing History |
| 2021-02-10 12:13 pm Sale | 2020-12-31 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 1,438,264 1.700% | -2,059,314 (-58.88%) | Filing History |
| 2020-07-16 4:22 pm Purchase | 2020-07-07 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 3,497,578 5.100% | 3,497,578 (New Position) | Filing History |